Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.
Am J Ther. 2011 Sep;18(5):375-81. doi: 10.1097/MJT.0b013e3181d7e1d3.
We aimed to describe the effects of parenteral bisphosphonates on bone mineral density (BMD) changes in primary biliary cirrhosis (PBC) patients with osteoporosis. Seventeen PBC patients with osteoporosis diagnosed between 1996 and 2005 were enrolled retrospectively. All patients received one of the following parenteral bisphosphonates: zoledronic acid, pamidronate disodium, or ibandronate sodium. The median (interquartile range) age of patients at osteoporosis diagnosis was 62.2 (56.4-67.9) and 94% were women. After treatment, percent change of lumbar spine bone mineral density (LS-BMD) and proximal femur BMD (PF-BMD) of patients with PBC was 2.9% and 0.4%, respectively. Eight patients (47%) showed a greater LS-BMD and/or PF-BMD with percent change of LS-BMD and PF-BMD of 8.7% and 0.8%, respectively. No serious adverse events were found. In PBC patients with osteoporosis, parenteral bisphosphonates can stabilize BMD for 47% of patients. More prospective studies are needed to evaluate the efficacy of specific parenteral bisphosphonates in patients with PBC and osteoporosis.
我们旨在描述骨质疏松症的原发性胆汁性肝硬化 (PBC) 患者中，静脉用双膦酸盐对骨密度 (BMD) 变化的影响。回顾性纳入了 1996 年至 2005 年间诊断为骨质疏松症的 17 名 PBC 患者。所有患者均接受了以下一种静脉用双膦酸盐治疗：唑来膦酸、帕米膦酸二钠或伊班膦酸钠。骨质疏松症诊断时患者的中位（四分位间距）年龄为 62.2（56.4-67.9）岁，94%为女性。治疗后，PBC 患者的腰椎骨密度 (LS-BMD) 和股骨近端骨密度 (PF-BMD) 的百分比变化分别为 2.9%和 0.4%。8 名（47%）患者的 LS-BMD 和/或 PF-BMD 增加，LS-BMD 和 PF-BMD 的百分比变化分别为 8.7%和 0.8%。未发现严重不良事件。在骨质疏松症的 PBC 患者中，静脉用双膦酸盐可使 47%的患者的 BMD 稳定。需要更多的前瞻性研究来评估特定的静脉用双膦酸盐在 PBC 和骨质疏松症患者中的疗效。
